Kailera Therapeutics, Inc.
KLRA
$14.69
-$0.15-1.01%
NASDAQ
| 06/30/2026 | 03/31/2026 | 06/30/2025 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | 20.31M | 13.79M | 11.13M | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 121.37M | 84.66M | 30.65M | ||
| Operating Income | -121.37M | -84.66M | -30.65M | ||
| Income Before Tax | -111.31M | -78.87M | -28.95M | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | -111.31M | -78.87M | -28.95M | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -111.31M | -78.87M | -28.95M | ||
| EBIT | -121.37M | -84.66M | -30.65M | ||
| EBITDA | -121.27M | -84.56M | -30.59M | ||
| EPS Basic | -1.09 | -3.65K | -- | ||
| Normalized Basic EPS | -0.68 | -2.28K | -- | ||
| EPS Diluted | -1.09 | -3.65K | -- | ||
| Normalized Diluted EPS | -0.68 | -2.28K | -- | ||
| Average Basic Shares Outstanding | 102.23M | 21.60K | -- | ||
| Average Diluted Shares Outstanding | 102.23M | 21.60K | -- | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||